首页> 外文OA文献 >Possible evolutionary relationships between streptomycin and bluensomycin biosynthetic pathways: detection of novel inositol kinase and O-carbamoyltransferase activities.
【2h】

Possible evolutionary relationships between streptomycin and bluensomycin biosynthetic pathways: detection of novel inositol kinase and O-carbamoyltransferase activities.

机译:链霉素和蓝霉素生物合成途径之间可能的进化关系:新型肌醇激酶和O-氨基甲酰基转移酶活性的检测。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bluensomycin (glebomycin) is an aminocyclitol antibiotic that differs structurally from dihydrostreptomycin in having bluensidine (1D-1-O-carbamoyl-3-guanidinodeoxy-scyllo-inositol) rather than streptidine (1,3-diguanidino-1,3-dideoxy-scyllo-inositol) as its aminocyclitol moiety. Extracts of the bluensomycin producer Streptomyces hygroscopicus form glebosus ATCC 14607 (S. glebosus) were found to have aminodeoxy-scyllo-inositol kinase activity but to lack 1D-1-guanidino-3-amino-1,3-dideoxy-scyllo-inositol kinase activity, showing for the first time that these two reactions in streptomycin producers must be catalyzed by different enzymes. S. glebosus extracts therefore possess the same five enzymes required for synthesis of guanidinodeoxy-scyllo-inositol from myo-inositol that are found in streptomycin producers but lack the next three of the four enzymes found in streptomycin producers that are required to synthesize the second guanidino group of streptidine-P. In place of a second guanidino group, S. glebosus extracts were found to catalyze a Mg2(+)-dependent carbamoylation of guanidinodeoxy-scyllo-inositol to form bluensidine, followed by a phosphorylation to form bluensidine-P. The novel carbamoyl-P:guanidinodeoxy-scyllo-inositol O-carbamoyltransferase and ATP:bluensidine phosphotransferase activities were not detected in streptomycin producers or in S. glebosus during its early rapid growth phase. Free bluensidine appears to be a normal intermediate in bluensomycin biosynthesis, in contrast to the case of streptomycin biosynthesis; in the latter, although exogenous streptidine can enter the pathway via streptidine-P, free streptidine is not an intermediate in the endogenous biosynthetic pathway. Comparison of the streptomycin and bluensomycin biosynthetic pathways provides a unique opportunity to evaluate those proposed mechanisms for the evolutionary acquisition of new biosynthetic capabilities that involve gene duplication and subsequent mutational changes in one member of the pair. In this model, there are at least five pairs of enzymes catalyzing analogous reactions that can be analyzed for homology at both the protein and DNA levels, including two putative pairs of inositol kinases detected in this study.
机译:Bluensomycin(glebomycin)是一种氨基环醇抗生素,其结构与二氢链霉素不同,其具有Bluensidine(1D-1-O-氨基甲酰基-3-guanidinodeoxy-scyllo-肌醇)而非streptidine(1,3-diguanidino-1,3-dideoxy-scyllo) -肌醇)作为其氨基环糖醇部分。发现蓝霉素生产商吸湿链球菌球菌ATCC 14607(S. glebosus)的提取物具有氨基脱氧鞘氨醇激酶活性,但缺乏1D-1-胍基-3-氨基-1,3-二脱氧鞘氨醇激酶。这表明链霉素生产者中的这两个反应必须由不同的酶催化。因此,希腊链球菌提取物具有在链霉素生产者中发现的从肌醇合成胍基去氧-鞘氨醇所需的五种酶,但缺乏在链霉素生产者中发现的合成第二种鸟苷所需的四种酶中的下三种。链霉菌素-P的组。代替第二个胍基团,发现金黄色葡萄球菌提取物催化胍基脱氧-scyllo-肌醇的Mg2(+)-依赖性氨基甲酰化形成bluensidine,随后磷酸化形成bluensidine-P。在链霉素生产者或球状链球菌的早期快速生长阶段,未检测到新的氨基甲酰基-P:胍基去氧-scyllo-肌醇O-氨基甲酰基转移酶和ATP:bluensidine磷酸转移酶的活性。与链霉素生物合成的情况相反,游离bluensidine似乎是bluensomycin生物合成中的正常中间体。在后者中,尽管外源性链霉菌素可以通过链霉菌素-P进入该途径,但游离的链烷啶不是内源性生物合成途径中的中间体。链霉素和蓝霉素生物合成途径的比较提供了一个独特的机会,可以评估这些拟议的机制,以进化地获得新的生物合成功能,其中涉及基因复制以及该对成员中的后续突变变化。在该模型中,至少有五对可催化类似反应的酶,可在蛋白质和DNA水平上分析同源性,包括在本研究中检测到的两对假定的肌醇激酶。

著录项

  • 作者

    Walker, J B;

  • 作者单位
  • 年度 1990
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号